E-cigarettes may be more effective in helping pregnant smokers quit

May.17.2022
E-cigarettes may be more effective in helping pregnant smokers quit
Pregnant smokers using e-cigarettes are more likely to quit smoking compared to nicotine patch users, according to a study.

Research shows that pregnant smokers are more likely to quit smoking using electronic cigarettes after four weeks than nicotine patches.

 

Researchers have discovered that electronic cigarettes may be equally safe for pregnant women trying to quit smoking as nicotine patches, and may even be a more effective tool.

 

Smoking during pregnancy increases the risk of adverse outcomes such as preterm birth, miscarriage, and low birth weight. However, quitting this habit can be a challenging process.

 

Dr. Francesca Pesola from Queen Mary University of London, the author of this new study, stated that "many pregnant smokers find it difficult to quit smoking using current cessation aids (including nicotine patches) and continue smoking throughout their pregnancy.

 

Although it has been discovered that electronic cigarettes are more effective than nicotine patches in helping people quit smoking, Pesola points out that despite the increasing use of electronic cigarettes by pregnant women, research on their effectiveness or safety is scarce.

 

After attempting to quit smoking for four weeks, 15.4% of individuals who reported using e-cigarettes said that they no longer smoke, compared to only 8.6% of those using nicotine patches.

 

Smoking during pregnancy increases the risk of negative outcomes, including premature birth, miscarriage, and low birth weight for the infant. However, quitting this habit can be a challenging process.

 

Although electronic cigarettes have been shown to be more effective than nicotine patches in helping people quit smoking, Pesola points out that despite an increase in the use of e-cigarettes among pregnant women, there is little research on their effectiveness or safety.

 

Researchers led by Pesola reported in the journal Nature Medicine that they randomly assigned 569 pregnant smokers to use e-cigarettes and 571 pregnant women to use nicotine patches – a nicotine replacement therapy that can already be prescribed during pregnancy. The participants were an average of 15.7 weeks pregnant and smoked 10 cigarettes per day.

 

Only 40% of participants received an electronic cigarette and 23% received a patch, both of which were used for at least four weeks. However, during the study period, those who received electronic cigarettes had higher usage rates and longer usage times.

 

Excluding participants who self-reported not smoking but using nicotine products other than those assigned to them, such as those using nicotine patches along with e-cigarettes, the research team found that those who received e-cigarettes appeared to do better in terms of smoking cessation.

 

After attempting to quit smoking for four weeks, 15.4% of individuals self-reported that they had not smoked, compared to only 8.6% of those who were given patches. At the end of their pregnancies, 19.8% of the e-cigarette group self-reported that they had quit smoking, while only 9.7% of the patch group had done so.

 

Only a small number of participants provided saliva samples to confirm smoking cessation at the end of pregnancy, but once those who used unassigned products were excluded, the research group found that the quit rates among the electronic cigarette group were higher.

 

Additionally, the research team found that the incidence of adverse events was similar between individuals who were given cigarettes and those who were given patches. More importantly, although the average birth weight of infants was similar, low birth weight was more common in the patch group.

 

However, this study has limitations, including low compliance and the use of electronic cigarettes that differ from modern devices.

 

The author further stated that due to the potential risks of nicotine during pregnancy, it is best for pregnant women to quit smoking without using nicotine-containing products.

 

Pesola stated, "We only recommend nicotine use for smokers who wish to quit traditional cigarettes.

 

However, she added, "The risks posed to mothers or infants by using electronic cigarettes are no greater than those posed by nicotine patches. Both are better choices than continuing to smoke throughout the entire course of pregnancy.

 

Source: The Guardian

 

E-cigarettes are equally safe as nicotine patches for pregnant women who smoke and are attempting to quit, according to a report in The Guardian on May 16, 2022.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
Product | R.J. Reynolds Launches Four Flavored Vuse Pro Pods for Vuse Alto Devices in U.S.
R.J. Reynolds Vapor Company has introduced Vuse Pro prefilled pods in Peach, Berry, Watermelon and Fresh Mint in selected U.S. states. Vuse’s U.S. website says the pods are intended for use with existing Vuse Alto devices. Each contains 2.0 mL of e-liquid at 5.0% nicotine by weight, uses nicotine salts and is offered in two- and four-pod packs. Reynolds said the rollout includes mandatory ID scanning for every purchase, purchase limits, stronger retailer-accountability requirements and strict age-restricted marketing standards. The four pods have not received marketing authorization from the U.S. Food and Drug Administration.
Sep.10
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19